Suchergebnisse - "Kenneth I Ataga"

PubPharm (9)

1

Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study

in: BMC Health Services Research | 2023

von Kwaku Marfo | Yvonne Dei-Adomakoh | Catherine Segbefia | +8

2

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS

in: HemaSphere | 2023

von Miguel Abboud | Julie Kanter | Kwaku Marfo | +7

3

Prospective Newborn Screening for Sickle Cell Disease and Other Inherited Blood Disorders in Central Malawi

in: International Journal of Public Health | 2021

von Gerald Tegha | Hillary M. Topazian | Hillary M. Topazian | +16

4

Drug Therapies for the Management of Sickle Cell Disease [version 1; peer review: 2 approved]

in: F1000Research | 2020

von Parul Rai | Kenneth I. Ataga

5

Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis.

in: PLoS ONE | 2020

von Kenneth I Ataga | Victor R Gordeuk | Irene Agodoa | +3

6

Clinical Implications of the Association of Fetal Hemoglobin with Peripheral Oxygen Saturation in Sickle Cell Disease

in: EBioMedicine | 2017

von Osheiza Abdulmalik | Kenneth I. Ataga

7

NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease.

in: PLoS ONE | 2017

von Joshua J Field | Elaine Majerus | Kenneth I Ataga | +4

8

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

enthalten in: The New England journal of medicine | 2017

von Kenneth I Ataga | Abdullah Kutlar | Julie Kanter | +13

9

Association of coagulation activation with clinical complications in sickle cell disease.

in: PLoS ONE | 2012

von Kenneth I Ataga | Julia E Brittain | Payal Desai | +6

1
[1]